BMJ 2007;335:691 (6 October), doi:10.1136/bmj.39356.348194.DB
News
Doctors disagree about directive on European clinical trials
Rory Watson
Brussels
| The first 150 words of the full text of this article appear below. |
Contradictory details are emerging of the impact that the three year old European Union legislation on clinical trials is having on medical science.
According to research presented on 27 September at a conference in Barcelona organised by the European Cancer Organisation, the number of non-commercial clinical trials has fallen by a quarter. Markus Hartmann, from European Consulting and Contracting in Oncology, Trier, Germany, told participants that this figure was a "conservative estimate."
But data from the European Medicines Evaluation Agency show that the percentage of non-commercial trials increased between 2005 and 2006. The agency and the European Commission launched consultations at a conference in London this week to analyse problems that the EU's clinical trials directive may have raised and to determine whether amendments to the legislation might be necessary.
Dr Hartmann based his research on six countries—the United Kingdom, Germany, France, Italy, Spain, and the Netherlands—all of which have
CiteULike 
Complore 
Connotea 
Del.icio.us 
Digg 
Reddit 
Technorati What's this?
This article
- Full text
- Respond to this article
- Alert me when this article is cited
- Alert me when responses are posted
- Alert me when a correction is posted
Services
- Email this article to a friend
- Find similar articles in BMJ
- Find similar articles in PubMed
- Add article to my folders
- Download to citation manager
- Request Permissions
Citing Articles
Google Scholar
PubMed
Related content
Bookmark with
What's new
Latest blogs
Services
Tools
Online poll
Resources
Rapid responses for this article
There are no rapid responses for this article.Most read last week
Print issues
